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A b s t r a c t: The aim of the study: Gastroesophageal reflux disease is a com-
mon disease with a multifactorial pathogenesis. Our aim was to analyse the role of the 
Gastroesophageal Disease Questionnaire in diagnosing reflux disease in the population 
of the Republic of Macedonia. 
Methods: The questionnaire on the severity of the symptoms related to GERD 
was used. An evaluation of the distal portion of the oesophagus was carried out in all 
patients with positive questionnaire results. All mucosal injury was classified by the Los 
Angeles criteria (LA). 
Results: 642 patients were included. 58.73%  females, with an average age of 
37.5 ± 8.2. Females had a higher BMI than males 26.8 ± 4.1 vs. 24.9 ± 3.8 p < 0.001. Of 
the total number of  examinees (642 patients), in those with erosive reflux disease and also 
in those with  nonerosive reflux disease, as shown respectively in endoscopy, the sensiti-
vity of  the RDQ was 100%, and the specifity was 0%. The100 sensitivity means that the 
questionnaire verified/diagnosed patients with erosive reflux disease with 100% certainty.  
Conclusions: Results were found in some studies comparing the positive Ref-
lux Disease Questionnaire and the level of erosive esophagitis (LA classification). This 
study provides evidence that the RDQ represents a viable instrument for assessing 
symptom severity and response to treatment in clinical trials of patients with GERD, but 
in patients with a high score, endoscopic evaluation should not be excluded 
 
Key words: Gastroesophageal reflux disease (GERD), Reflux Disease Questionnaire, 
Upper Endoscopy. 
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Introduction 
 
Gastroesophageal reflux disease (GERD) is a chronic condition in which 
reflux of stomach contents causes troublesome symptoms and/or complications 
[1]. The disease can present in the form of a range of oesophageal and extra-
osofageal syndromes, but its cardinal symptoms are heartburn and regurgitation.  
In 2006 a world-wide consensus was published, in which a pathophysiological-
oriented basis for the definition of GERD was employed, and its possible cli-
nical presentations described as oesophageal or extra-oesophageal syndromes 
which may manifest alone or in combination [2]. 
GERD is presumably the most common disease of the digestive tract 
that brings large numbers of patients to physicians every day. It lowers the 
quality of life of affected individuals and exposes them to potentially dangerous 
complications. An increasing awareness exists among patients, doctors and 
authorities of the relevance of this pathological condition. Despite an improved 
understanding of many aspects of gastroesophageal reflux disease, clinical 
management of several cases is still unsatisfactory. Atypical cases with extra-
oesophageal manifestations often defy diagnosis. Even typical symptoms are 
often misunderstood and considered to be part of the poorly defined area of 
dyspepsia by both patients and doctors. Roughly one half of the adult popu-
lation in industrialized countries have personal experience of reflux symptoms, 
and 20–30% suffer from the disease [3]. Symptoms associated with GERD 
include heartburn, acid regurgitation and chest pain as well as “extra-oesopha-
geal” manifestations such as nausea, chronic coughing, asthma and hoarseness. 
All the symptoms may compromise the health-related quality of life [4–6]. 
Symptom-focused questionnaires have an important role in clinical trials of 
gastroesofageal reflux disease management.  
 
 
The aim of the study 
 
Gastroesophageal reflux disease (GERD) is diagnosed based on sym-
ptoms. Various countries have published several guidelines, recommendations 
and questionnaires for the diagnosis and management of GERD [7, 8]. There 
was no data on patients in the Republic of Macedonia. The purpose of this study 
was to register and analyse the distribution of GERD symptoms in patients in 
the Republic of Macedonia in correlation with sex, age, BMI and life style. It 
was also to analyze the correlation between endoscopic findings and a positive 
reflux questionnaire. 
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Patients and Methods 
 
This three-year prospective study clinical trial was conducted at the 
University Gastroenterohepatology Clinic and gathered data from 642 patients 
with GERD symptoms. Patients between 18 and 55 years old were included (we 
restricted older people to decrease the risk of malignancy) with a clinical history 
of heartburn, acid regurgitation, or both during the previous 3 months. All the 
participants were asked to respond to the questionnaire, along with another 
detailed questionnaire consisting of 16 original questions. An additional 12 ques-
tions included enquiries about symptoms related to the upper gastrointestinal 
tract, medical history, lifestyle factors, etc. Upper endoscopy was performed on 
all patients. 
All subjects were interviewed by the physician, and their weight (with 
minimal clothing) and standing height were recorded at the clinic. BMI was 
calculated with a formula. 
Those who had a negative endoscopy finding and positive symptom 
questionnaire and who signed an agreement underwent a 24-hour pH monito-
ring. A PPI two-week test was done on those who did not agree to have a 24 
pH-monitoring test. 
Subjects with major symptoms of malignancy, oesophageal stenosis, 
previous gastrointestinal surgery (except cholecystectomy), cardiovascular dise-
ase, intake of alcohol, drugs, severe psychiatric disorder, pregnancy, or brea-
stfeeding were excluded. Those patients who were using proton pump inhibi-
tors, H2 antagonist, glucocorticoid or ketoconazole 2 weeks before the endo-
scopy were also excluded. 
 
 
GERD diagnosis 
 
Endoscopic findings 
Endoscopy was carried out at pretreatment of the patients who gave 
agreement and evaluated according to the 2nd modified Los Angeles (LA) clas-
sification [9, 10] (Grade N, no endoscopic mucosal changes; Grade M, minimal 
changes; Grade A, one or more mucosal breaks = 5 mm long that do not extend 
between the tops of two mucosal folds; Grade B, one or more mucosal breaks > 
5 mm long that do not extend between the tops of two mucosal folds; Grade C, 
one or more mucosal breaks that are continuous between the tops of two or 
more mucosal folds, but do not involve the entire oesophageal circumference; 
and Grade D, a mucosal break that involves the entire esophageal circumfe-
rence).  
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Reflux Disease Questionnaire (RDQ) 
 
Symptom-focused questionnaires have an important role in clinical trials of 
gastroesophageal reflux disease (GERD) management. This is especially the 
case given that symptom relief is a major goal of treatment for patients with 
GERD [11], and that a patient’s self-report on symptom status is now believed 
to be more reliable than a physician’s assessment [12]. To assess the GERD 
symptoms, several questionnaires have been proposed, such as QUEST [13], 
Manterola’s Scale [14], FSSG (Frequency Scale for the Symptoms of GERD) 
[15], Zimmerman’s Scale [16], and so forth. Whereas typical symptoms of 
GERD are heartburn and regurgitation [17], it is well known that GERD pati-
ents present very diverse symptoms [1]. In the present study, we chose FSSG 
scoring, as it can evaluate not only the acid-reflux related symptoms but also the 
dyspeptic symptoms [15–16]. 
The questionnaire for the Macedonian population was made as a modifi-
cation of GERDAS (gastroesophageal reflux disease symptom assessment scale), 
the Majo Clinic questionnaire and the frequency scale for the symptoms of GERD 
(FSSG) [19]. It was designed to measure patient perception of the severity of 
symptoms of GERD. The questionnaire was in the and the Albanian language. 
In the first part age, sex and Body Mass Index are notified. In the second part 
patients should answer 16 questions, for every question two answers should be 
given. These answers are used for qualification of the symptoms (Table 1).  
 
Table 1 
 
GERD Questionnaire 
Symptoms Symptom strength Frequency 
Chest pain   
Pyrosis   
Regurgitation   
Throat burning   
Hoarseness   
Throat pain   
Need to clear throat   
Chonic cough   
Dysphagia   
Nose to throat secretion   
Feeling of a lump in the throat   
Tongue burning   
Laringeal spasm   
Otitis media inflammation   
Sleeping disturbency   
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Two answers should be indicated: 
1. Symptom strength: 0 – absent; 1 – mild/can be ignored; 2 – modera-
te/cannot be ignored, but do not disturb the way of life; 3 – severe/symptoms 
affect the way of life; 4 – very severe/seriously disturb the way of life  
2. Frequency of symptoms: 0 – none; 1 – once a year; 2 – less than once 
a month; 3 – once a month; 4 – once a week; 5 – several times during the week; 
6 – daily. 
The additional 12 questions include enquiries about symptoms related 
to the upper gastrointestinal tract, medical history, lifestyle factors and so on: 
1) Do you take any proton pump inhibitors (PPIs)? 
2) Do you take any histamine H2 – receptor antagonists (H2 RAs)? 
3) Do you take any digestive drugs other than antacids (PPIs or H2 
RAs)? 
4) Do you have a history of cardiovascular disease? 
5) Has your body weight markedly increased in adulthood (more than 
10kg from age 20)? 
6) Have you lost weight in the  last 3 months which could be caused by 
problems of the disease? 
7) Do you have a feeling of inadequate sleep? 
8) Do you have a habit of having dinner within two hours before going 
to bed? 
9) Do you have a habit of quick eating? 
10) Do you have a habit of smoking? 
11) Do you have a habit of drinking alcohol (almost every day)? 
12) Do you have a habit of eating spicy food? 
Answer: "yes" or "no" 
 
 
Statistics 
 
Univariate statistics were used to examine means, standard deviations 
and shapes of distribution for continuous variables and frequencies for catego-
rical variables. Missing or extreme values were identified and corrected as 
necessary; no data were imputed. Study participant test scores were eliminated 
if all questions on a test were answered with the same answer choice. For 
bivariate analysis, outcome measures were examined using t-tests for variables 
with two categories, the Mann-Whitney U Test and one-way ANOVA for vari-
ables with more than two categories.  
Multiple linear regression was used to determine the relationship bet-
ween GERD manifestation and quality of life outcomes while controlling for 
potential confounding factors (age, gender, race, BMI, current alcohol use, current 
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smoking, current use of spicy food, current use of an antireflux medication and 
comorbidity) and patient perception of GERD severity. Subjects with missing 
data on relevant variables were excluded from the multivariable analyses.  
 
 
Results 
 
We recruited 642 patients. Of these, (58.73% females) subjects had 
complete data and were included in the analysis. The average age was 37.5 ± -8.2 
years (no gender difference). 
BMI for females was higher than males (26.8 ± 4.1 vs. 24.9 ± 3.8, p < 0.001) 
 
Table 2  
 
General data and BMI associated with grade of oesophageal damage (mean +/-SE)                                            
 None A B C-D p-value 
n(F/M) 72/46 112/84 178/120 22/8 < 0.001 
Age(years) 37.5(0.5) 38.2(0.4) 39.1(0.4) 41.2 (1.2) < 0.001 
BMI < 25 35 60 82 3 0.159 
BMI 25–30 65 88 163 20 0.026 
BMI > 30 18 48 53 7 < 0.001 
 
Oesophageal damage differed by sex: men had severe LA(C-D damage) 
[OR 5 3.7, 95% CI 1.7–8.2] and mild damage (B damage) [OR51.56, 95% 
CI 1.1–2.3] compared to women and this was associated with BMI: lesions 
grade C-D in BMI between 25 and 30 was OR52.8 (95% CI 1.16–6.7) and for 
those with BMI > 30, OR52.1 (95% CI 0.65–6.8), compared to BMI < 25. 
The mean value of the questionnaire score for all pts.was 7.61 ± 3.10 
(min = 3 and max = 15). 
Endoscopic finding were negative in 120 (18.3%) and positive in 504 
(81.7%) pts. 
There is a statistically significant difference between patients with negative 
and positive endoscopic findings according to mean values of questionnaire 
score Mann-Whitney U Test: Z = - 9.54 p = 0.000001) (Table 3 and Fig. 1) 
 
Table 3  
 
Mean values of questionnaire score according to endoscopic findings 
Endoscopic findings Mean SD 
negative  3.42 0.50 
positive 8.57 2.60 
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Figure 1 – Mean values of questionnaire score according endoscopic findings 
 
Table 4  
 
Mean values of questionnaire score according to endoscopic findings 
Endoscopic finding Mean SD Number of pts. 
negative  3.42 0.50 120 
A 5.89 1.25 180 
B 9.84 1.37 300 
C - D 13.89 0.78 42 
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Figure 2 – Mean values of questionnaire score according to endoscopic findings 
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Analysis of variables (ANOVA) showed that in patients with different 
endoscopic findings there were big differences according to the disease que-
stionnaire score (F = 403.87 p = 0.00000). According to the Tukey HSD test, 
between all groups of evaluated patients (none, A, B and C-D) there are sta-
tistically significant differences according to the disease questionnaire score (p 
= 0.00001) (Table 4 and Fig. 2) 
 
Table 5  
 
Sensitivity and specificity of reflux disease questionnaire in patients  
with erosive and non-erosive reflux disease 
Endoscopic finding Questionnaire 
positive negative 
total 
positive 522 120 642 
negative 0 0 0 
total 522 120 642 
Se = 100%    Sp = 0 
 
In the total number of examinees (642 patients), those with erosive 
reflux disease, also those  nonerosive reflux disease, shown in endocopy respe-
ctively, the sensitivity of  the RDQ is 100%, and specificity is 0%. The 100% 
sensitivity means that the quesionnaire verified/diagnosed patients with erosive 
reflux disease with 100% certainty. 
 
 
Discussion 
 
The RDQ was developed to facilitate the identification of GERD in pri-
mary care and this was the setting in which its psychometric properties were esta-
blished [20]. This study demonstrated the utility of the RDQ in evaluating treat-
ment response in a clinical trial of a new medication. The questionnaire effec-
tively differentiated various levels of patient-assessed symptom severity compa-
red to physician-assessed severity. Consistency of performance in the two langua-
ges was also observed. The study population, being highly enriched for GERD, pre-
cluded determination of the predictive validity of the RDQ for a GERD diagnosis. 
The European observational study made in 2009 by Javier P Gisbert et 
al. shows that the heterogeneous population of primary care patients who seek 
medical attention for GERD continue to experience substantial impairment of 
their daily lives, as shown by RDQ and GIS scores. Indeed, the combined use of 
the questionnaires provided a comprehensive overview of the frequency, inten-
sity and impact of GERD symptoms on patients' daily lives, aspects that would 
not necessarily have been captured by the use of one questionnaire alone [21]. 
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Thus, RDQ allowed for an evaluation of the frequency and intensity of GERD 
symptoms, the GIS providing complementary information in terms of the use of 
additional medication for GERD symptoms and the impact of such symptoms 
on work and daily productivity, eating/drinking and sleep. An association bet-
ween GERD and sleep disturbance was apparent, and has more impact on the 
daily lives of GERD patients than atypical GERD-related symptoms such as 
coughing, hoarseness, and difficulty swallowing food [22–23]. 
Our study concluded that in patients with erosive reflux disease the sen-
sitivity of the disease questionnaire is 100%, but a larger number of patients is 
needed to prove the results of the study. Also a group with negative endoscopic 
findings which have positive RDQ, and positive PPI test or positive 24-pH-
metry should be part of the investigation. 
 
 
Conclusion 
 
Gastroesophageal reflux disease is a common problem that is expensive 
to diagnose and treat in primary and specialised settings. GERD is increasing in 
prevalence in the Western world, as well as in the Republic of Macedonia, with 
important risk factors being obesity and life style. 
The sensitivity to classic reflux symptoms in our study was 65% for 
diagnosing the GERD. The response to PPI has good sensitivity (76%). Out-
patient oesophageal pH testing is the most sensitive for the GERD, but there is 
the problem of agreement for it to be performed. Endoscopy is most specific for 
diagnosing GERD with oesophageal damages.   
This study provides evidence that the RDQ represents a viable instru-
ment for assessing symptom severity and response to treatment in clinical trials 
of patients with GERD, but in patients with a high score, endoscopic evaluation 
should not be excluded.  
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Aп s t r a k t: Cel na studijata: Gastroezofagealnata bolest e ~esto 
zaboluvawe so multifakoriјalna patogeneza. Na{ata cel be{e da ja odre-
dime ulogata na pra{alnikot za gastroezofaгealen refluks vo дijagnosti-
kata na refluksnata bolest на poпulacijata vo Republika Makedonija. 
Metodi: Pra{alnikot za te`ina na simptomite na gastroezofa-
geаlna refluksna bolest be{e primenuvan kaj site проsleduvani pacienti. 
Endoskopska evaluacija na hranovodot, `eludnikot i dvanaestopale~noto 
crevo be{e napravena kaj site pacienti so pozitiven pra{alnik. Site mu-
kozni o{tetuvawa bea klasificirani spored Los Anџeleskata klasifi-
kacija. 
Rezultati: 642 pacienti bea vklu~eni vo studijata, 58,73% `eni so 
prose~na starost od 37,5 ± 8,2. Bodi mas indeksot kaj `enite be{e pogolem 
отколку kaj ma`ite 26,8 ± 4,1 nasproti 24,9 ± 3,8 p < 0,001. Kaj vkupniot broj 
na ispitanici (N = 642), odnosno i kaj onie koi imaat erozii i kaj onie koi 
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nemaat erozii pri endoskopija, senzitivnosta na pra{alnikot e 100%, a 
specifi~nosta e 0%. Senzitivnost 100% zna~i deka pra{alnikot so 100% 
sigurnost gi verifikuva/dijagnosticira site koi imaat refluksna bolest i  
prisustvo na erozii. 
Zaklu~oci: Rezultatite od odделni studii gi sporeduvaat pozitiv-
niot par{alnik za refluksnata bolest so nivoto na erozivniot ezofagitis 
spored Los Anџeleс klasifikacijaта. Ovaa studija uka`a deka pra{alni-
kot za refluksnata bolest e instrument vo dijagnostikata na pacientite so 
GERD so erozivni o{tetувања na hranoprovodnikot, koи{to ne mo`ат da 
bidат zanemarenи. Sepak kaj pacientite so visok skor na pra{alnikot 
endoskopskoto isleduvawe ne treba da bide isklu~eno. 
 
Клучни зборови: gastroezofagealna рефлуксна bolest (GERD), прашалник за 
рефлуксна болест, ендоскопија. 
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